Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation

a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations.  These risks and uncertainties related to the transaction with Cardiogenesis include that the tender offer and merger may not be completed within our anticipated time frame, if at all, and a sufficient number of Cardiogenesis shareholders may not choose to tender their stock in the offer and/or vote for the proposed merger.  Two purported class action lawsuits have been filed by Cardiogenesis shareholders challenging the merger.  Also, competing offers may be made for Cardiogenesis, various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit or delay the transaction, and the effects of disruption from the transaction may make it more difficult to maintain relationships with employees, customers, business partners or governmental entities.  Furthermore, CryoLife's ability to fully realize the anticipated benefits of the transaction with Cardiogenesis may be materially adversely impacted if the integration of Cardiogenesis' business with CryoLife is slower than expected or unsuccessful, or if the transaction and subsequent efforts to integrate Cardiogenesis' business with CryoLife distracts CryoLife's management team from the other facets of CryoLife's business.  Forward-looking statements in this press release should be evaluated together with the risk factors detailed in CryoLife's Securities and Exchange Commission filings, including its Form 10-K filing for the year ended December 31, 2010, and CryoLife's other SEC filings.  CryoLife does not undertake to update its forward-looking statements.

Notice to Investors

The tender offer for the outstanding common stock of Cardiogenesis Corporation referred to in this press release commenced on April 5, 2011.  This press release is neither an offer to purchase

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
(Date:7/28/2015)... , ... July 29, 2015 , ... The new Xsample 530 sample changer for ... a wide range of liquid viscosities – from less than 12,000 mPas (internal air) up ... vials. , What immediately catches the eye about Xsample 530 is its removable magazine, ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
(Date:7/28/2015)... ... July 28, 2015 , ... In ... billion in 2013; while production volume reached close to 1.84 million tonnes in ... a share of 75.5% of the region’s total aluminium hydroxide production; the country’s ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Biomedical Refrigerators and Freezers Market - ... Forecast 2014 - 2022" report to their ... and freezers market has been segmented based on ... banks, and others. The others segment includes applications ...
Breaking Biology Technology:New Moves in Automatic Sample Handling: Introducing Xsample 530 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
... weeks back, I suggested that the role of IT professional is ... this picture in my head of urgent communiqus and hushed conversations, ... colliding in the middle of tense situations that could boil over ... patience and a great deal of flexibility is the order of ...
... Educators and software developers will have the chance to ... at the first annual Games+Learning+Society conference at ... being held by Games And Professional Practice Simulations, a ... Co-Lab and a group of instructors at the UW-Madison ...
... Joe Hogan, head of GE Healthcare Technologies in Waukesha, will ... London next year as part of the parent company's effort ... succeed Bill Castell as head of GE Healthcare in 2006. ... Waukesha-based GE Healthcare Technologies division since 2000, when he succeeded ...
Cached Biology Technology:IT is the New Foreign Service 2IT is the New Foreign Service 3Education conference to draw together games researchers 2
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with t